Multimodale Therapie beim lokal fortgeschrittenen Magenkarzinom

Zusammenfassung

Lokal fortgeschrittene Magenkarzinome sind durch eine ungünstige Prognose charakterisiert, die jedoch verbessert werden kann, wenn die chirurgische Therapie in ein multimodales Behandlungskonzept eingebettet ist. Die angestrebten Ziele einer neoadjuvanten Therapie liegen in der präoperativen Reduktion des Primärtumors, einer Verbesserung der T- und N-Kategorie und einer frühen Therapie von Mikrometastasen. In kontrollierten klinischen Studien konnte gezeigt werden, dass eine neoadjuvante Chemotherapie als auch eine kombinierte Radiochemotherapie bei Tumoren des gastroösophagealen Übergangs zu einer Verbesserung der primären R₀-Resektionsrate, des progressionsfreien Überlebens und des Gesamtüberlebens führt. Insbesondere Patienten mit lokal fortgeschrittenen Tumoren profitieren von diesem Konzept, während in frühen Tumorstadien dieses kontrovers diskutiert wird. Nonresponder profitieren von der neoadjuvanten Therapie nicht, wodurch einer Response-Evaluation bzw. Response-Prädiktion eine besondere Bedeutung zukommt. Da bei fortgeschrittenen Karzinomen die Wahrscheinlichkeit für Lymphknotenmetastasen hoch ist, sollte auch nach erfolgreicher neoadjuvanter Therapie eine Gastrektomie mit D₂-Lymphadenektomie durchgeführt werden. Der Artikel beschreibt aktuelle Entwicklungen auf diesem Gebiet.

Abstract

Locally advanced gastric cancers are characterized by poor prognosis. Clinical outcome can be improved if surgery becomes part of a multimodal treatment approach. The purpose of neoadjuvant treatment includes downsizing of the primary tumor, improvement of the T- and N- categories, and early therapy of micrometastasis. Several controlled clinical trials showed that neoadjuvant chemotherapy as well as neoadjuvant combined radio-chemotherapy, especially for tumors of the gastroesophageal junction, can improve the rate of primary R0 resections, relapse-free survival, and overall survival. While patients with locally advanced tumors clearly benefit from this strategy, the approach is still controversial in patients with early stage disease. Nonresponders do not benefit from neoadjuvant therapy. Therefore, response evaluation and response prediction are of great importance. After successful neoadjuvant chemotherapy, patients should undergo gastrectomy with D₂-lymphadenectomy because of a high probability of lymph node metastasis. This article summarizes current developments in this field.

Neoadjuvant - Chemotherapie - Radiochemotherapie - Magenkarzinom

neoadjuvant - chemotherapy - radio chemotherapy - gastric cancer

Literatur

• 1 Barbour A P, Rizk N P, Gerdes H. et al . Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction.  J Am Coll Surg. 2007;  205 593-596
• 2 Barbour A P, Rizk N P, Gonen M. et al . Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.  Ann Surg. 2007;  246 1-8
• 3 Becker K, Langer R, Reim D. et al . Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.  Ann Surg. 2011;  253 934-939
• 4 Beer A J, Wieder H A, Lordick F. et al . Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.  Radiology. 2006;  239 472-480
• 5 Boige V, Pignon J P, Saint-Aubert B. et al . Final results of a randomized trial comparing preoperative 5-fluorouracil (F) cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC Accord07-FFCD 9703 trial.  J Clin Oncol. 2007;  25 4510
• 6 Brücher B L, Becker K, Lordick F. et al . The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.  Cancer. 2006;  106 2119-2127
• 7 Brücher B L, Swisher S G, Königsrainer A. et al . Response to preoperative therapy in upper gastrointestinal cancers.  Ann Surg Oncol. 2009;  16 878-886
• 8 Buyse M, Pignon J. Meta-analysis of randomized trials assessing the interest of postoperative chemotherapy and prognostic factors in gastric cancer.  J Clin Oncol. 2009;  25 211
• 9 Chang F, Deere H, Mahadeva U. et al . Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues.  Am J Clin Pathol. 2008;  129 252-262
• 10 Cunningham D, Allum W H, Stenning S P. et al . MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.  N Engl J Med. 2006;  355 11-20
• 11 Dikken J L, Jansen E P, Cats A. et al . Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.  J Clin Oncol. 2010;  28 2430-2436
• 12 Earle C C, Maroun J A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revistiting a meta-analysis of randomized trials.  Eur J Cancer. 1999;  35 1059-1064
• 13 Feussner H, Hartl F. Staging laparoscopy in oncology.  Chirurg. 2006;  77 971-980
• 14 Fiorica F, Di Bona D, Schepis F. et al . Preoperative chemoradiotherapy in oesophageal cancer: a systematic review and meta-analysis.  Gut. 2004;  53 925-930
• 15 Gebski V, Burmeister B, Smithers B M. et al . Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.  Lancet Oncol. 2007;  8 226-234
• 16 Heidecke C D, Weinghardt H, Feith M. et al . Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy.  Surgery. 2002;  132 495-501
• 17 Janunger K G, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis.  Eur J Surg Oncol. 2002;  168 597-608
• 18 Jensen A D, Grehn C, Nikoghosyan A. et al . Catch me if you can – the use of image guidance in the radiotherapy of an unusual case of esophageal cancer.  Strahlenther Onkol. 2009;  185 469-473
• 19 Jouve J, Michel P, Mariette C. et al . Fédération Francophone de Cancérologie Digestive. Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus.  J Clin Oncol. 2008;  26 4555
• 20 Kim S, Lim D H, Lee J. et al . An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.  Int J Radia Oncol Biol Phys. 2005;  63 1279-1285
• 21 Leibl B J, Vitz S, Schäfer W. et al . Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity.  Strahlenther Onkol. 2011;  187 231-237
• 22 Lordick F, Ott K, Krause B J. et al . PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.  Lancet Oncol. 2007;  8 797-805
• 23 Lordick F, Ruers T, Aust D E. et al . European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer.  Eur J Cancer. 2008;  44 1807-1819
• 24 Lordick F, Stein H J, Peschel C. et al . Neoadjuvant therapy for oesophagogastric cancer.  Br J Surg. 2004;  91 540-551
• 25 Lowy A M, Mansfield P F, Leach S D. et al . Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer.  Ann Surg. 1999;  229 303-308
• 26 Macdonald J S, Smalley S R, Benedetti J. et al . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.  N Engl J Med. 2001;  345 725-730
• 27 Mari E, Floriani I, Tinazzi A. et al . Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of puplished randomized trials. A study of the GISCAD.  Ann Oncol. 2000;  11 837-843
• 28 Mizumoto M, Sugahara S, Nakayama H. et al . Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer.  Strahlenther Onkol. 2010;  186 482-488
• 29 Napieralski R, Ott K, Kremer M. et al . Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: Relation to therapy response and clinicopathologic and molecular features.  Clin Cancer Res. 2007;  13 5095-5102
• 30 Ott K, Fink U, Becker K. et al . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.  J Clin Oncol. 2003;  21 4604-4610
• 31 Ott K, Herrmann K, Lordick F. et al . Early metabolic response evaluation by fluorine-18 fluorodesoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long term results of a prospective study.  Clin Cancer Res. 2008;  14 2012-2018
• 32 Ott K, Vogelsang H, Marton N. et al . The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer.  Int J Cancer. 2006;  119 2885-2894
• 33 Ott K, Vogelsang H, Mueller J. et al . Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.  Clin Cancer Res. 2003;  9 2307-2315
• 34 Ott K, Weber W A, Lordick F. et al . Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.  J Clin Oncol. 2006;  24 4692-4698
• 35 Saka M, Mudan S S, Katai H. et al . Pancreaticoduodenectomy for advanced gastric cancer.  Gastric Cancer. 2005;  8 1-5
• 36 Sakuramoto S, Sasako M, Yamaguchi T. et al . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.  N Engl J Med. 2007;  357 1810-1820
• 37 Sasako M, Sano T, Yamamoto S. et al . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.  N Engl J Med. 2008;  359 453-462
• 38 Sasako M, Sano T, Yamamoto S. et al . Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.  Lancet Oncol. 2006;  7 644-651
• 39 Schneider P M, Baldus S E, Metzger R. et al . Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.  Ann Surg. 2005;  242 684-692
• 40 Schuhmacher C, Böttcher K, Siewert J R. Intestinal pouches: gastric reconstruction.  Chirurg. 1999;  70 520-529
• 41 Schuhmacher C P, Fink U, Becker K. et al . Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin and cisplatin. Closing results after 5 years of follow-up.  Cancer. 2001;  91 918-927
• 42 Schumacher C, Schlag P, Lordick F. et al . Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia; Ranomized EORTC phase III trial.  J Clin Oncol. 2006;  27 4510
• 43 Schuhmacher C, Gretschel S, Lordick F. et al . Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40 954.  J Clin Oncol. 2010;  28 5210-5218
• 44 Schwartz G K, Winter K, Minsky B D. et al . Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regiments as adjuvant therapy in resected gastric cancer (RTOG-0114).  J Clin Oncol. 2009;  27 1956-1962
• 45 Songun I, Putter H, Kranenbarg E M. et al . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.  Lancet Oncol. 2010;  11 439-449
• 46 Stahl M, Walz M K, Stuschke M. et al . Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.  J Clin Oncol. 2009;  27 851-856
• 47 Stahl M, Wilke H, Stuschke M. et al . Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer.  J Cancer Res Clin Oncol. 2005;  131 67-72
• 48 Stein H J, Feith M, Siewert J R. Neoadjuvante Therapie im oberen Gastrointestinaltrakt, Aktuelle Konzepte beim Barrett-Karzinom.  Chirurg. 2009;  80 1019-1022
• 49 Tepper J E, Krasna M, Niedzwiecki D. et al . Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781.  J Clin Oncol. 2006;  24 4012
• 50 Urba S G, Orringer M B, Turrisi A. et al . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.  J Clin Oncol. 2001;  19 305-313
• 51 Van Cutsem E, Kang Y, Chung H. et al . Efficacy results of the Toga trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).  J Clin Oncol. 2009;  27 204
• 52 van der Gaast A V, van Hagen P, Hulshof M. et al .Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized pase III study ASCO meeting 2010. 
• 53 Walsh T N, Noonan N, Hollywood D. et al . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.  N Engl J Med. 1996;  335 462-467
• 54 Weber W A, Ott K, Becker K. et al . Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.  J Clin Oncol. 2001;  19 3058-3065
• 55 Wieder H A, Beer A J, Lordick F. et al . Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.  J Nucl Med. 2005;  46 2029-2034
• 56 Wilke H, Preusser P, Fink U. et al . New developments in the treatment of gastric carcinoma.  Cancer Treat Res. 1991;  55 363-373
• 57 Wolf M, Zehentmayr F, Niyazi M. et al . Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.  Strahlenther Onkol. 2010;  186 374-381
• 58 Wu C W, Hsiung C A, Lo S S. et al . Nodal dissection for patients with gastric cancer: a randomised controlled trial.  Lancet Oncol. 2006;  7 309-315
• 59 Zhang Z X, Gu X Z, Yin W B. et al . Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) – report on 370 patients.  Int J Radiat Oncol Biol Phys. 1998;  42 929-934